Slingshot members are tracking this event:

Ixekizumab Demonstrates Rapid, Clinically Meaningful Improvements as Early as One Week among Patients with Moderate-to-Severe Plaque Psoriasis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
LLY Community voting in process

Additional Information

Additional Relevant Details  Eli Lilly and Company announced today that treatment for moderate-to-severe plaque psoriasis with ixekizumab resulted in clinically meaningful improvements as early as one week, compared to patients treated with etanercept or placebo. Detailed results of this combined analysis of UNCOVER-2 and UNCOVER-3 were presented during the American Academy of Dermatology (AAD) Annual Meeting taking place March 4-8in Washington, D.C.UNCOVER-2 and UNCOVER-3 are double-blind, multicenter, Phase 3 studies evaluating more than 2,500 patients with moderate-to-severe plaque psoriasis across 19 countries. In these comparator studies, patients were assigned to receive either placebo, etanercept (50 mg twice a week) or ixekizumab (80 mg every two or four weeks) for 12 weeks, following a 160-mg starting dose.This combined analysis evaluated the speed of onset of clinical improvement as measured by mean percentage improvement in Psoriasis Area Severity Index (PASI) score from baseline, as well as time to PASI 50 and PASI 75 among patients treated with ixekizumab, etanercept or placebo. PASI measures the extent and severity of psoriasis by assessing average redness, thickness and scaliness of skin lesions (each graded on a zero to four scale), weighted by the body surface area of involved skin.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 04, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Uncover-2, Uncover-3, Skin Lesions, Plaque Psoriasis, Dermatologic Diseases, Psoriasis Plaques